# US 2023/0279172 A1 · Radiopaque polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0279172 A1
- Document ID: US20230279172A1
- Status: Published application
- Kind: A1
- Application number: 18/317,747
- Filed: 2023-05-15
- Published: 2023-09-07
- Earliest claimed: 2018-06-29
- Assignees: Boston Scientific Medical Device Limited
- Applicants: Boston Scientific Medical Device Limited
- Inventors: Andrew Lennard Lewis; Hugh Britton; Yiqing Tang; Jonathan Vince; Koorosh Ashrafi; Damien Guégan
- Web page: https://patentgrep.com/patent/US20230279172A1

## CPC

- C08F 261/04: on to polymers of vinyl alcohol
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 49/0442: {Polymeric X-ray contrast-enhancing agent comprising a halogenated group}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)}
- C07C 47/565: all hydroxy groups bound to the ring
- C07C 47/575: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 229/62: with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
- C07C 309/11: with the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C08F 2/14: Organic medium
- C08F 8/28: Condensation with aldehydes or ketones
- C08F 8/30: Introducing nitrogen atoms or nitrogen-containing groups
- C08F 8/48: Isomerisation; Cyclisation
- C08F 290/12: Polymers provided for in subclasses C08C or C08F
- C08G 67/00: Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing oxygen or oxygen and carbon, not provided for in groups C08G2/00 - C08G65/00
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- C08F 2810/30: leading to the formation or introduction of aliphatic or alicyclic unsaturated groups
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

This invention relates to radiopaque polymers and to their use, particularly in the manufacture of medical devices and in methods of medical treatment, including therapeutic embolization. In particular embodiments the present disclosure relates to a hydrophilic polymer comprising pendent groups which a phenyl ring is substituted with one or more iodine groups and one or more non-iodine groups as described in more detail herein.

## Claims

### Claim 1

A hydrophilic polymer comprising pendent groups of the formula I:
wherein:
W is independently selected from —OH, —COOH, —SO3H, —OPO3H, —O—(C1-4 alkyl), —O—(C1-4 alkyl)OH, —O—(C1-4 alkyl)R2, —O—(C2H5O)qR1, —(C═O)—O—C1-4 alkyl and O—(C═O)C1-4 alkyl; or a group -BZ;
B is a bond, or a straight branched alkanediyl, oxyalkylene, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and
Z is an ammonium, phosphonium, or sulphonium phosphate or phosphonate ester zwitterionic group;
X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S;
G is a coupling group through which the group of the formula I is coupled to the polymer and is selected from ether, ester, amide, carbonate, carbamate, 1,3 dioxolone, and 1,3 dioxane;
R1 is H or C1-4 alkyl;
R2 is —COOH, —SO3H, or —OPO3H2
q is an integer from 1 to 4;
n is an integer from 1 to 4;
p is an integer from 1 to 3; and
n + p is from 2 to 5; and
wherein —COOH, —OPO3H2 and —SO3H as well as phenolic —OH may be in the form of a pharmaceutically acceptable salt.

### Claim 2 (depends on 1)

The polymer of claim 1 which is a polyhydroxylated polymer and G is selected from ether, ester, carbonate, carbamate, 1,3 dioxolone, and 1,3 dioxane.

### Claim 3 (depends on 1)

The polymer of claim 1 which is a polycarboxylated polymer and G is selected from ester and amide.

### Claim 4 (depends on 1)

The polymer of claim 1 which is a co-polymer of polyvinyl alcohol and wherein the groups of the formula I are coupled through hydroxyl groups of the polyvinyl alcohol.

### Claim 5 (depends on 4)

The polymer of claim 4 comprising groups of the formula Ia or Ib:
wherein
G is a coupling group through which the group of the formula Ia is coupled to the polymer and is selected from ether, ester, carbonate or carbamate.

### Claim 6 (depends on 1)

The polymer of claim 1 in which n is two or three.

### Claim 7 (depends on 1)

The polymer of claim 1 in which the phenyl ring of the group of the formula I is 3,5 diiodinated, 3,4,5 triiodinated or 2,4,6 triiodinated.

### Claim 8

A polymer according to any preceding claim in which p is 1.

### Claim 9 (depends on 1)

The polymer of claim 1 in which W is independently selected from —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4 alkyl), —O—(C1-4 alkyl)OH, —O—(C1-4 alkyl)R2, —O—(C2H5O)qR1,
(C═O)—O—C1-4 alkyl and —O—(C═O)C1-4 alkyl or a group -BZ, wherein B is a bond, a branched or non-branched C1-6 alkanediyl group or a branched or non-branched C1-6 oxyalkylene group; and
Z is a group of formula II
wherein A3 and A4, are the same or different and are selected from —O—, —S—, and —NH—
; W1 is —W2—N+R43, in which W2 is C1-6 alkanediyl and R4 are the same or different and each is hydrogen or C1-4 alkyl; and
wherein —OH, —COOH, —OPO3H2 and —SO3H may be in the form of a pharmaceutically acceptable salt.

### Claim 10 (depends on 1)

The polymer of claim 1 in which W is selected from —OH, —COOH, —SO3H, —OPO3H2,
O—(C1-4 alkyl)R2 and —O—(C2H5O)qR1; wherein —OH, —COOH, —OPO3H2 and —SO3H may be in the form of a pharmaceutically acceptable salt.

### Claim 11 (depends on 1)

The polymer claim 1 in which the phenyl ring of the group of the formula I, Ia or Ib is substituted in one of the following patterns:
.

### Claim 12 (depends on 1)

The polymer of claim 1 which is cross-linked.

### Claim 13 (depends on 1)

The plymer of claim 1 in the form of a hydrogel comprising greater than 50%.

### Claim 14 (depends on 1)

The polymer of claim 1 having an iodine content of greater than 10 mg iodine per cm3 of fully hydrated polymer.

### Claim 15 (depends on 1)

The polymer of claim 1 which has a radiodensity of greater than 500 HU.

### Claim 16 (depends on 1)

The ploymer of claim 1 which has a radiodensity of greater than 1000 HU.

### Claim 17 (depends on 1)

The polymer of claim 1 which is substituted by groups, other than those in W, which are charged by pH 7.4.

### Claim 18 (depends on 1)

A flowable composition comprising the polymer of claim 1.

### Claim 19 (depends on 1)

A composition comprising the polymer of claim 1.

### Claim 20 (depends on 19)

The composition comprising the polymer of claim 19, as a solution in either an aqueous solvent or organic solvent which is miscible with water.
